SHANGHAI – The CFDA has an unenviable task on its hands. The agency has an enormous workload supporting the world's second-largest drug market, made more complex given it is still in a developing phase. Regulators not only have to keep up with up an 18 percent year-on-year increase in drug applications that require their review and assessment, they are simultaneously trying to construct the legal architecture necessary to regulate the industry overall.